Synapse - Howard Scher

Results (1133)

Tumor-specific serum peptidome patterns

Meeting Abstract

Tempst, P.; Villanueva, J.; Shaffer, D. R.; Martorella, A.; Robson, M. E.; Lawlor, K.; Philip, J.; Fleisher, M.; Lilja, H.; Holland, E. C.; more...
Cancer Research (2006)

Fulltext@MSK | Save

Phase I trial results of PCK3145 in patients (pts) with castrate metastatic prostate cancer (PC) - The US experience

Meeting Abstract

Slovin, S. F.; Daigneault, L.; Dulude, H.; Panchal, C.; Richardson, J.; Curley, T.; Delacruz, A.; Fleisher, M.; Morris, M.; Scher, H.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Psychostimulants for fatigue in prostate cancer

Meeting Abstract

Roth, A. J.; Nelson, C. J.; Rosenfeld, B.; O'Shea, N.; Slovin, S.; Scher, H. I.; Breitbart, W.
Psycho-Oncology (2006)

Fulltext@MSK | Save

A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastorna multiforme (GBM)

Meeting Abstract

Nguyen, T. D.; Lassman, A. B.; Lis, E.; Rosen, N.; Shaffer, D. R.; Scher, H. I.; Deangelis, L. M.; Abrey, L. E.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM)

Meeting Abstract

Nguyen, T. D.; Lassman, A. B.; Lis, E.; Rosen, N.; Shaffer, D. R.; Scher, H. I.; Deangelis, L. M.; Abrey, L. E.
Neuro-Oncology (2006)

Fulltext@MSK | Save

Phase 2 trial of (177)Lutetium (Lu-177) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (Lu-177-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)

Meeting Abstract

Morris, M. J.; Milowsky, M. I.; Pandit-Taskar, N.; Divgi, C.; David, K. A.; Rozario, C. P.; Vallabhajosula, S.; Goldsmith, S. J.; Scher, H. I.; Nanus, D. M.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC)

Meeting Abstract

Milowsky, M. I.; Galsky, M.; George, D. J.; Lewin, J. M.; Rozario, C. P.; Marshall, T.; Chang, M.; Nanus, D. M.; Webb, I. J.; Scher, H. I.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

The probability of a positive bone scan in patients who were treated with adrogen ablasio therapy for rising PSA after radical prostatectomy

Meeting Abstract

Dotan, Z. A.; Sathyamoorthy, K.; Bianco, F. J.; Stephenson, A. J.; Eastham, J. A.; Fearn, P.; Schoder, H.; Scher, H. I.; Scardino, P. T.; Kattan, M. W.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Systems pathology for building predictive models: The androgen receptor as a prototype biomarker in prostate cancer progression and targeted therapeutic response assessment

Meeting Abstract

Donovan, M. J.; Scher, H.; Scardino, P.; Kotsianti, A.; Cordon-Cardo, C.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events

Meeting Abstract

Basch, E. M.; McDonough, T.; Iasonos, A.; Siegel, E.; Culkin, A.; Kris, M.; Scher, H. I.; Schrag, D.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save